Welcome!

News Feed Item

Five New Human Studies Completed by Greenleaf Medical AB Since 2013 NutrAward Win for Best New Ingredient

Global Leader in Nutraceutical Research and Development Announces Results of Five Human Studies and Two Animal Trials

STOCKHOLM, SWEDEN -- (Marketwired) -- 03/08/14 -- Since winning NutrAward's 'Best New Ingredient' at Nutracon in March 2013, Greenleaf Medical's Appethyl ™ has been the subject of five new successful clinical trials. These five human studies and two animal trials have affirmed both the appetite suppression and weight loss effects found in the original pilot trials.

Appethyl™ is the tradename for the clinically-tested appetite suppression product from spinach that is being brought to the marketplace by Greenleaf Medical (GLM), a Swedish company that has licensed the patented technology from Lund University in Sweden.

In the clinical trials completed in 2013, Appethyl has been shown to provide the following key benefits:

1. Significantly reducing appetite four to six hours after ingesting the product with a meal. In addition, post hoc analysis showed that there was no difference between 3.7g and 7.4g dose as both doses were equally effective in reducing both hunger and thinking about food at four hours.(1)

2. Significantly reducing cravings for sweets after the first dose of 5 g, but even more significantly after 90 days and throughout the entire day.(2)

3. Significant weight loss and fat loss as well as significant loss in waist circumference compared to placebo in a very well-controlled (DBPC), 12 week independent clinical trial utilizing 2.5g given twice daily.(3)

Post-market analysis has also provided additional insights including a common experience being an increase in appetite suppression over three to four days. This effect is interesting since there is published clinical data supporting a significant reduction in appetite after just one dose which is now further supported by another yet to be published clinical trial. In addition, there are many reports of individuals feeling better when they take the product, which may be explained by one of those 100 or so proteins found in the active thylakoids found within Appethyl and one in particular, rubisco.

Two animal trials were also completed in 2013, which helped expand the physiological effects of this proprietary spinach extract. The first trial investigated the effects of Appethyl on the gut flora in rats while the second investigated the effects of Appethyl on CCK and blood glucose and insulin in pigs fed only glucose. The results are summarized below:

1. Rats fed Appethyl™ for just 10 days resulted in a significant prebiotic effect increasing the growth of Lactobacillus reuteri, a beneficial probiotic, as well as producing a completely different fecal flora from that of the control group. In addition, the product was found to significantly reduce food intake as well as a 60% lower plasma insulin levels two hours after ingesting an oral glucose tolerance test (OGTT).(4) The novel prebiotic finding is the basis for a new patent application.

2. Pigs fed Appethyl along with receiving OGTT resulted in significantly lower blood glucose levels within the first hour, greater CCK within just 30 min and an even more significant drop in ghrelin between 2 and 4 hours post-ingestion.(5)

Since the 2013 NutraAward win, Greenleaf Medical celebrated their first product launch of Appethyl in Sweden. Sales numbers surpassed projections, as Appethyl was the number one selling nutraceutical in the largest health food store chain in Sweden within weeks of its introduction to the market. Appethyl sold out in the first few days of its Swedish launch resulting in sales of $1.2 million in the first week in Sweden alone, where the population is only 9.5 million, less than a twentieth of the United States population.

For more information on Appethyl ™ or Greenleaf Medical, please visit http://www.gl-medical.com or contact Maria Soderberg at +46 70 869 27 06, (GMT +1) email: ms(at)gl-medical(dot)com.

About Greenleaf Medical AB
Greenleaf Medical is a Swedish research and development company, active in the global nutraceutical market, which sells and develops natural ingredients with well-documented, beneficial health effects. Greenleaf Medical works together with universities and international science and regulatory groups. Their products are used in both Functional Food and Dietary Supplements.

Greenleaf Medical believes the secret of health and beauty is based on finding the best ingredients through scientific validation. Dedicated to creating natural products with published mechanism-of-action and efficacy studies, the Greenleaf Medical team believes in the unique composition of natural, active ingredients and innovative formula of their supplements.

References:
(1) Stenblom EL, Montelius C, Ostbring K, Hakansson M, Nilsson S, Rehfeld JF, Erlanson-Albertsson C. Supplementation by thylakoids to a high carbohydrate meal decreases feelings of hunger, elevates CCK levels and prevents postprandial hypoglycaemia in overweight women. Appetite 2013;68:118-23.
(2) Erlanson-Albertsson C, Montelius C, Erlandsson D, Vitija E, Egecioglu E, Podgórski K. Suppressed urge for sweet and release of GLP-1 in overweight women through consumption of green plant thylakoids. Presented at 5th Swiss Winter Conference on Ingestive Behavior, March 3, 2014, St Moritz, Swiss.
(3) Unpublished data.
(4) Montelius C, Osman N, Wstrom B, Ahrne S, Molin G, Albertsson P-A, Erlanson-Albertsson C. Feeding of spinach thylakoids to rat modulates the gut microbiota, decreases food intake and affects the insulin response. Journal of Nutritional Science 2013;2:1-9.
(5) Montelius C, Szwiec K, Kardas M, Lozinska L, Erlanson-Albertsson C, Pierzynowski S, Rehfeld JF, Weström B. Dietary thylakoids suppress blood glucose and modulate appetite-regulating hormones in pigs exposed to oral glucose tolerance test. Clinical Nutrition. 2014.

Elizabeth Maxim
Media Contact
Email Contact
Phone: +1 (310) 994-7381

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Organizations do not need a Big Data strategy; they need a business strategy that incorporates Big Data. Most organizations lack a road map for using Big Data to optimize key business processes, deliver a differentiated customer experience, or uncover new business opportunities. They do not understand what’s possible with respect to integrating Big Data into the business model.
Companies are harnessing data in ways we once associated with science fiction. Analysts have access to a plethora of visualization and reporting tools, but considering the vast amount of data businesses collect and limitations of CPUs, end users are forced to design their structures and systems with limitations. Until now. As the cloud toolkit to analyze data has evolved, GPUs have stepped in to massively parallel SQL, visualization and machine learning.
The session is centered around the tracing of systems on cloud using technologies like ebpf. The goal is to talk about what this technology is all about and what purpose it serves. In his session at 21st Cloud Expo, Shashank Jain, Development Architect at SAP, will touch upon concepts of observability in the cloud and also some of the challenges we have. Generally most cloud-based monitoring tools capture details at a very granular level. To troubleshoot problems this might not be good enough.
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busine...
Enterprises have taken advantage of IoT to achieve important revenue and cost advantages. What is less apparent is how incumbent enterprises operating at scale have, following success with IoT, built analytic, operations management and software development capabilities – ranging from autonomous vehicles to manageable robotics installations. They have embraced these capabilities as if they were Silicon Valley startups. As a result, many firms employ new business models that place enormous impor...
SYS-CON Events announced today that Taica will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Taica manufacturers Alpha-GEL brand silicone components and materials, which maintain outstanding performance over a wide temperature range -40C to +200C. For more information, visit http://www.taica.co.jp/english/.
SYS-CON Events announced today that Dasher Technologies will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Dasher Technologies, Inc. ® is a premier IT solution provider that delivers expert technical resources along with trusted account executives to architect and deliver complete IT solutions and services to help our clients execute their goals, plans and objectives. Since 1999, we'v...
Recently, REAN Cloud built a digital concierge for a North Carolina hospital that had observed that most patient call button questions were repetitive. In addition, the paper-based process used to measure patient health metrics was laborious, not in real-time and sometimes error-prone. In their session at 21st Cloud Expo, Sean Finnerty, Executive Director, Practice Lead, Health Care & Life Science at REAN Cloud, and Dr. S.P.T. Krishnan, Principal Architect at REAN Cloud, will discuss how they b...
We all know that end users experience the Internet primarily with mobile devices. From an app development perspective, we know that successfully responding to the needs of mobile customers depends on rapid DevOps – failing fast, in short, until the right solution evolves in your customers' relationship to your business. Whether you’re decomposing an SOA monolith, or developing a new application cloud natively, it’s not a question of using microservices – not doing so will be a path to eventual b...
SYS-CON Events announced today that TidalScale, a leading provider of systems and services, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. TidalScale has been involved in shaping the computing landscape. They've designed, developed and deployed some of the most important and successful systems and services in the history of the computing industry - internet, Ethernet, operating s...
SYS-CON Events announced today that MIRAI Inc. will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MIRAI Inc. are IT consultants from the public sector whose mission is to solve social issues by technology and innovation and to create a meaningful future for people.
SYS-CON Events announced today that IBM has been named “Diamond Sponsor” of SYS-CON's 21st Cloud Expo, which will take place on October 31 through November 2nd 2017 at the Santa Clara Convention Center in Santa Clara, California.
The next XaaS is CICDaaS. Why? Because CICD saves developers a huge amount of time. CD is an especially great option for projects that require multiple and frequent contributions to be integrated. But… securing CICD best practices is an emerging, essential, yet little understood practice for DevOps teams and their Cloud Service Providers. The only way to get CICD to work in a highly secure environment takes collaboration, patience and persistence. Building CICD in the cloud requires rigorous ar...
Join IBM November 1 at 21st Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA, and learn how IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Cognitive analysis impacts today’s systems with unparalleled ability that were previously available only to manned, back-end operations. Thanks to cloud processing, IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Imagine a robot vacuum that becomes your personal assistant tha...
Data scientists must access high-performance computing resources across a wide-area network. To achieve cloud-based HPC visualization, researchers must transfer datasets and visualization results efficiently. HPC clusters now compute GPU-accelerated visualization in the cloud cluster. To efficiently display results remotely, a high-performance, low-latency protocol transfers the display from the cluster to a remote desktop. Further, tools to easily mount remote datasets and efficiently transfer...